HomeCompareAXPG vs ABBV

AXPG vs ABBV: Dividend Comparison 2026

AXPG yields 18.07% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $37.5K in total portfolio value· pulled ahead in Year 8
10 years
AXPG
AXPG
● Live price
18.07%
Share price
$11.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.8K
Annual income
$5,450.80
Full AXPG calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AXPG vs ABBV

📍 ABBV pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAXPGABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AXPG + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AXPG pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AXPG
Annual income on $10K today (after 15% tax)
$1,535.57/yr
After 10yr DRIP, annual income (after tax)
$4,633.18/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,422.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AXPG + ABBV for your $10,000?

AXPG: 50%ABBV: 50%
100% ABBV50/50100% AXPG
Portfolio after 10yr
$83.6K
Annual income
$15,111.28/yr
Blended yield
18.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AXPG
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AXPG buys
0
ABBV buys
0
No recent congressional trades found for AXPG or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAXPGABBV
Forward yield18.07%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$64.8K$102.3K
Annual income after 10y$5,450.80$24,771.77
Total dividends collected$34.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AXPG vs ABBV ($10,000, DRIP)

YearAXPG PortfolioAXPG Income/yrABBV PortfolioABBV Income/yrGap
1$12,507$1,806.55$11,550$430.00+$957.00AXPG
2$15,494$2,111.57$13,472$627.96+$2.0KAXPG
3$19,023$2,444.75$15,906$926.08+$3.1KAXPG
4$23,160$2,805.28$19,071$1,382.55+$4.1KAXPG
5$27,973$3,191.91$23,302$2,095.81+$4.7KAXPG
6$33,534$3,603.04$29,150$3,237.93+$4.4KAXPG
7$39,918$4,036.77$37,536$5,121.41+$2.4KAXPG
8← crossover$47,203$4,490.91$50,079$8,338.38$2.9KABBV
9$55,471$4,963.10$69,753$14,065.80$14.3KABBV
10$64,804$5,450.80$102,337$24,771.77$37.5KABBV

AXPG vs ABBV: Complete Analysis 2026

AXPGStock

The Leverage Shares 2x Long AXP Daily ETF (AXPG) is a 2x Daily Leveraged (Bull) ETF designed for active traders seeking to magnify short-term results. The AXPG ETF aims to achieve two times (200%) the daily performance of AXP stock, minus fees and expenses.

Full AXPG Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AXPG vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AXPG vs SCHDAXPG vs JEPIAXPG vs OAXPG vs KOAXPG vs MAINAXPG vs JNJAXPG vs MRKAXPG vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.